QURT · Quarta-Rad, Inc.

Quarta-Rad, Inc. (QURT) reported Q1 FY2026 results reflecting challenges in its dual-segment operations of Quarta-Rad radiation detection and Sellavir AI-driven software, amid a strategic pivot from historical products. Revenue fell 21.4% year-over-year to $25.9K from $32.9K, primarily due to decreased sales in both Quarta-Rad and Sellavir, with the latter impacted by delayed revenue recognition. This decline underscores the transitional pressures as management shifts primary focus toward AI software and analytics solutions, while maintaining limited activities in legacy radiation detection.

Gross profit marked a significant turnaround to $6.2K positive from a -$1.4K loss prior year, delivering a gross margin of 24.0%. The improvement stems from a lower cost of goods sold base aligned with reduced sales volume, providing a margin bright spot despite top-line weakness.

Operating income deteriorated 5.6% to -$94.9K from -$89.9K, with the operating margin at -367.2%. The increase in loss was primarily due to higher operating expenses, attributable to Sellavir’s ramp-up activities. Net income followed suit, widening 34.6% to -$104.2K from -$77.4K, while diluted EPS remained stable at -$0.01. These dynamics highlight expense pressures outpacing revenue recovery in the early stages of the AI pivot.

Cash flow from operations reflected heightened investment needs, with net cash use rising to -$58.3K from -$13.3K. This acceleration signals liquidity strain from the operational shift, as the company operates two segments under going concern considerations from recurring losses.

Management commentary emphasizes funding operations through existing cash balances, generated revenues, related party support, and potential capital raises or strategic arrangements if needed. Accounts receivable are carried at expected collection values, supporting working capital assumptions. No plans exist for employee changes over the next three months, with current officers, directors, and contractors deemed sufficient. Investors should monitor Sellavir progress, including software pilots and international resellers, as catalysts to mitigate cash burn and build recurring revenue against ongoing funding risks.